Full Text Journal Articles by
Author David E Gerber

Advertisement

Find full text journal articles






Increasing Numbers and Reported Adverse Events in Patients with Lung Cancer Undergoing Inpatient Lung Biopsies: A Population-Based Analysis.

Mitchell S von Itzstein, Arjun Gupta, Kristin C Mara, Sahil Khanna, David E Gerber,

INTRODUCTION:The use of molecular biomarkers to guide lung cancer management has led to increasing frequency and amounts of tissue required for repeat lung biopsies. While patient safety and reporting of adverse events has been increasingly emphasized in recent decades, the safety of lung biopsies in patients with lung cancer has ... Read more >>

Lung (Lung)
[2019, :]

Cited: 0 times

View full text PDF listing >>



Autoimmunity, checkpoint inhibitor therapy and immune-related adverse events: A review.

Shaheen Khan, David E Gerber,

Immune checkpoint inhibitors have emerged as a remarkable treatment option for diverse cancer types. However, a significant number of patients on checkpoint inhibitors develop immune-related adverse events (irAEs) affecting a wide variety of organs. These events, which may reflect enhanced T cell activation, are unpredictable, heterogeneous, and in some instances ... Read more >>

Semin. Cancer Biol. (Seminars in cancer biology)
[2019, :]

Cited: 0 times

View full text PDF listing >>



Advertisement

Efficacy of EGFR plus TNF inhibition in a preclinical model of temozolomide-resistant glioblastoma.

Gao Guo, Ke Gong, Vineshkumar Thidil Puliyapaddamba, Nishah Panchani, Edward Pan, Bipasha Mukherjee, Ziba Damanwalla, Sabrina Bharia, Kimmo J Hatanpaa, David E Gerber, Bruce E Mickey, Toral R Patel, Jann N Sarkaria, Dawen Zhao, Sandeep Burma, Amyn A Habib,

BACKGROUND:Glioblastoma (GBM) is the most common primary malignant adult brain tumor. Temozolomide (TMZ) is the standard of care and is most effective in GBMs that lack the DNA repair protein MGMT. Moreover, even initially responsive tumors develop a secondary resistance to TMZ and become untreatable. Since aberrant EGFR signaling is ... Read more >>

Neuro-oncology (Neuro-oncology)
[2019, :]

Cited: 0 times

View full text PDF listing >>



Patient and provider perspectives on delivery of oral cancer therapies.

Caitlin C Murphy, Simon J Craddock Lee, David E Gerber, John V Cox, Hannah M Fullington, Robin T Higashi,

OBJECTIVE:The introduction of oral cancer therapies presents new challenges to delivery of quality cancer care. Little is known about how patients and providers address and overcome these challenges. We conducted a qualitative study exploring the range of patient and provider perspectives on oral cancer therapies. METHODS:We conducted semi-structured interviews with ... Read more >>

Patient Educ Couns (Patient education and counseling)
[2019, :]

Cited: 0 times

View full text PDF listing >>



Immunotherapy for non-small cell lung cancer: from clinical trials to real-world practice.

Sawsan Rashdan, David E Gerber,

Transl Lung Cancer Res (Translational lung cancer research)
[2019, 8(3):202-207]

Cited: 0 times

View full text PDF listing >>



Conceptual Model for Accrual to Cancer Clinical Trials.

Simon J Craddock Lee, Caitlin C Murphy, Ann M Geiger, David E Gerber, John V Cox, Rasmi Nair, Celette Sugg Skinner,

J. Clin. Oncol. (Journal of clinical oncology : official journal of the American Society of Clinical Oncology)
[2019, 37(23):1993-1996]

Cited: 0 times

View full text PDF listing >>



Newer-Generation EGFR Inhibitors in Lung Cancer: How Are They Best Used?

Tri Le, David E Gerber,

The FLAURA trial established osimertinib, a third-generation epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI), as a viable first-line therapy in non-small cell lung cancer (NSCLC) with sensitizing EGFR mutations, namely exon 19 deletion and L858R. In this phase 3 randomized, controlled, double-blind trial of treatment-naïve patients with EGFR ... Read more >>

Cancers (Basel) (Cancers)
[2019, 11(3):]

Cited: 0 times

View full text PDF listing >>



Development and Validation of a Nomogram Prognostic Model for Patients With Advanced Non-Small-Cell Lung Cancer.

Tao Wang, Rong Lu, Sunny Lai, Joan H Schiller, Fang Liz Zhou, Bo Ci, Stacy Wang, Xiaohan Gao, Bo Yao, David E Gerber, David H Johnson, Guanghua Xiao, Yang Xie,

Importance:Nomogram prognostic models can facilitate cancer patient treatment plans and patient enrollment in clinical trials. Objective:The primary objective is to provide an updated and accurate prognostic model for predicting the survival of advanced non-small-cell lung cancer (NSCLC) patients, and the secondary objective is to validate a published nomogram prognostic model ... Read more >>

Cancer Inform (Cancer informatics)
[2019, 18:1176935119837547]

Cited: 0 times

View full text PDF listing >>



Checkpoint Inhibitor Pneumonitis: Too Clinically Serious For Benefit?

Tri Le, John D Minna, David E Gerber,

J Thorac Oncol (Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer)
[2019, 14(3):332-335]

Cited: 0 times

View full text PDF listing >>



Unique mutation patterns in anaplastic thyroid cancer identified by comprehensive genomic profiling.

Saad A Khan, Bo Ci, Yang Xie, David E Gerber, Muhammad S Beg, Steven I Sherman, Maria E Cabanillas, Naifa L Busaidy, Barbara A Burtness, Andreas M Heilmann, Mark Bailey, Jeffrey S Ross, David J Sher, Siraj M Ali,

INTRODUCTION:Anaplastic thyroid cancer (ATC) is a highly aggressive thyroid cancer. Those ATC with genomic alterations (GAs) in TSC2, ALK, and BRAF may respond to targeted therapies. METHODS:Comprehensive genomic profiling on 90 ATC specimens identified base substitutions, short insertions and deletions, amplifications, copy number alterations, and genomic rearrangements in up to ... Read more >>

Head Neck (Head & neck)
[2019, 41(6):1928-1934]

Cited: 0 times

View full text PDF listing >>



Mobile Device Applications for Electronic Patient Portals in Oncology.

Kelvin K Pho, Rong Lu, Samantha Gates, Jennifer Cai, Donglu Xie, Yang Xie, Simon J Craddock Lee, David E Gerber,

PURPOSE:Mobile devices provide individuals with rapid and frequent access to electronic patient portals. We investigated how oncology patients use this technology to review test results and communicate with providers. PATIENTS AND METHODS:We performed a retrospective study of patients enrolled in the MyChart electronic health portal associated with the Epic electronic ... Read more >>

JCO Clin Cancer Inform (JCO clinical cancer informatics)
[2019, 3:1-8]

Cited: 0 times

View full text PDF listing >>



Hyperprogressive disease: a distinct effect of immunotherapy?

Vinita Popat, David E Gerber,

J Thorac Dis (Journal of thoracic disease)
[2019, 11(Suppl 3):S262-S265]

Cited: 0 times

View full text PDF listing >>



NQO1-dependent, Tumor-selective Radiosensitization of Non-small Cell Lung Cancers.

Edward A Motea, Xiumei Huang, Naveen Singh, Jessica A Kilgore, Noelle S Williams, Xian-Jin Xie, David E Gerber, Muhammad S Beg, Erik A Bey, David A Boothman,

PURPOSE:Development of tumor-specific therapies for the treatment of recalcitrant non-small cell lung cancers (NSCLC) is urgently needed. Here, we investigated the ability of β-lapachone (β-lap, ARQ761 in clinical form) to selectively potentiate the effects of ionizing radiation (IR, 1-3 Gy) in NSCLCs that overexpress NAD(P)H:Quinone Oxidoreductase 1 (NQO1). EXPERIMENTAL DESIGN:The ... Read more >>

Clin. Cancer Res. (Clinical cancer research : an official journal of the American Association for Cancer Research)
[2019, 25(8):2601-2609]

Cited: 0 times

View full text PDF listing >>



Immune dysregulation in cancer patients developing immune-related adverse events.

Shaheen Khan, Saad A Khan, Xin Luo, Farjana J Fattah, Jessica Saltarski, Yvonne Gloria-McCutchen, Rong Lu, Yang Xie, Quan Li, Edward Wakeland, David E Gerber,

BACKGROUND:Up to 40% of cancer patients on immune checkpoint inhibitors develop clinically significant immune-related adverse events (irAEs). The role of host immune status and function in predisposing patients to the development of irAEs remains unknown. METHODS:Sera from 65 patients receiving immune checkpoint inhibitors and 13 healthy controls were evaluated for ... Read more >>

Br. J. Cancer (British journal of cancer)
[2019, 120(1):63-68]

Cited: 0 times

View full text PDF listing >>



Phase 1 study of ARQ 761, a β-lapachone analogue that promotes NQO1-mediated programmed cancer cell necrosis.

David E Gerber, M Shaalan Beg, Farjana Fattah, Arthur E Frankel, Oluwatomilade Fatunde, Yull Arriaga, Jonathan E Dowell, Ajit Bisen, Richard D Leff, Claudia C Meek, William C Putnam, Raja Reddy Kallem, Indhumathy Subramaniyan, Ying Dong, Joyce Bolluyt, Venetia Sarode, Xin Luo, Yang Xie, Brian Schwartz, David A Boothman,

BACKGROUND:NAD(P)H:quinone oxidoreductase 1 (NQO1) is a two-electron oxidoreductase expressed in multiple tumour types. ARQ 761 is a β-lapachone (β-lap) analogue that exploits the unique elevation of NQO1 found in solid tumours to cause tumour-specific cell death. METHODS:We performed a 3+3 dose escalation study of 3 schedules (weekly, every other week, ... Read more >>

Br. J. Cancer (British journal of cancer)
[2018, 119(8):928-936]

Cited: 0 times

View full text PDF listing >>



Treatment and Outcomes of Primary Pericardial Mesothelioma: A Contemporary Review of 103 Published Cases.

Elizabeth McGehee, David E Gerber, Joan Reisch, Jonathan E Dowell,

Primary pericardial mesothelioma (PPM) is a rare cancer for which there is no consensus on treatment. We evaluated and summarized a large contemporary population of published PPM cases to characterize risk factors, treatment patterns, and clinical outcomes. Using Ovid and PubMed, literature published from 2000 through 2016 was searched using ... Read more >>

Clin Lung Cancer (Clinical lung cancer)
[2019, 20(2):e152-e157]

Cited: 0 times

View full text PDF listing >>



Statistical justification of expansion cohorts in phase 1 cancer trials.

Ali A Mokdad, Xian-Jin Xie, Hong Zhu, David E Gerber, Daniel F Heitjan,

BACKGROUND:Phase I cancer trials increasingly incorporate dose-expansion cohorts (DECs), reflecting a growing demand to acquire more information about investigational drugs. Protocols commonly fail to provide a sample-size justification or analysis plan for the DEC. In this study, we develop a statistical framework for the design of DECs. METHODS:We assume the ... Read more >>

Cancer (Cancer)
[2018, 124(16):3339-3345]

Cited: 0 times

View full text PDF listing >>



Prevalence of Prior Cancer Among Persons Newly Diagnosed With Cancer: An Initial Report From the Surveillance, Epidemiology, and End Results Program.

Caitlin C Murphy, David E Gerber, Sandi L Pruitt,

Importance:The US cancer survivor population is rapidly growing. Cancer survivors are frequently excluded from cancer clinical trials and observational research. Objective:To examine prevalence of prior cancer among individuals newly diagnosed with cancer. Design, Setting, and Participants:Linked observations across the population-based Surveillance, Epidemiology, and End Results (SEER) program of cancer registries ... Read more >>

JAMA Oncol (JAMA oncology)
[2018, 4(6):832-836]

Cited: 1 time

View full text PDF listing >>



Diagnosis and management of pulmonary toxicity associated with cancer immunotherapy.

Sawsan Rashdan, John D Minna, David E Gerber,

Pulmonary toxicity of cancer immunotherapies has emerged as an important clinical event that requires prompt identification and management. Although often referred to as pneumonitis, pulmonary toxicity associated with immunotherapy covers a broad and overlapping spectrum of pulmonary manifestations, and, once suspected, the range of differential diagnoses of infectious and neoplastic ... Read more >>

Lancet Respir Med (The Lancet. Respiratory medicine)
[2018, 6(6):472-478]

Cited: 0 times

View full text PDF listing >>



Outcomes of neoadjuvant and adjuvant chemotherapy in stage 2 and 3 non-small cell lung cancer: an analysis of the National Cancer Database.

Matthew MacLean, Xin Luo, Shidan Wang, Kemp Kernstine, David E Gerber, Yang Xie,

The current recommendation for the treatment of stage II and III NSCLC is surgery with chemotherapy. While the convention is to administer chemotherapy postoperatively (adjuvant chemotherapy), inconsistent results have been reported regarding the administration of chemotherapy preoperatively (neoadjuvant chemotherapy). Therefore, a comprehensive analysis of neoadjuvant chemotherapy use in NSCLC is ... Read more >>

Oncotarget (Oncotarget)
[2018, 9(36):24470-24479]

Cited: 1 time

View full text PDF listing >>



Estimating lead-time bias in lung cancer diagnosis of patients with previous cancers.

Zhiyun Ge, Daniel F Heitjan, David E Gerber, Lei Xuan, Sandi L Pruitt,

Surprisingly, survival from a diagnosis of lung cancer has been found to be longer for those who experienced a previous cancer than for those with no previous cancer. A possible explanation is lead-time bias, which, by advancing the time of diagnosis, apparently extends survival among those with a previous cancer ... Read more >>

Stat Med (Statistics in medicine)
[2018, 37(16):2516-2529]

Cited: 0 times

View full text PDF listing >>



Development and Validation of a Nomogram Prognostic Model for SCLC Patients.

Shidan Wang, Lin Yang, Bo Ci, Matthew Maclean, David E Gerber, Guanghua Xiao, Yang Xie,

INTRODUCTION:SCLC accounts for almost 15% of lung cancer cases in the United States. Nomogram prognostic models could greatly facilitate risk stratification and treatment planning, as well as more refined enrollment criteria for clinical trials. We developed and validated a new nomogram prognostic model for SCLC patients using a large SCLC ... Read more >>

J Thorac Oncol (Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer)
[2018, 13(9):1338-1348]

Cited: 0 times

View full text PDF listing >>



Nivolumab Plus Erlotinib in Patients With EGFR-Mutant Advanced NSCLC.

Scott Gettinger, Matthew D Hellmann, Laura Q M Chow, Hossein Borghaei, Scott Antonia, Julie R Brahmer, Jonathan W Goldman, David E Gerber, Rosalyn A Juergens, Frances A Shepherd, Scott A Laurie, Tina C Young, Xuemei Li, William J Geese, Naiyer Rizvi,

INTRODUCTION:This phase I study evaluated nivolumab combined with erlotinib in patients with advanced EGFR-mutant NSCLC. METHODS:Patients with advanced EGFR-mutant NSCLC who were EGFR tyrosine kinase inhibitor (TKI)-naive or TKI-treated but had not received chemotherapy were treated with nivolumab 3 mg/kg every 2 weeks and erlotinib 150 mg/d until disease progression or ... Read more >>

J Thorac Oncol (Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer)
[2018, 13(9):1363-1372]

Cited: 2 times

View full text PDF listing >>



Safety and efficacy of concurrent immune checkpoint inhibitors and hypofractionated body radiotherapy.

Osama Mohamad, Alberto Diaz de Leon, Samuel Schroeder, Andrew Leiker, Alana Christie, Elizabeth Zhang-Velten, Lakshya Trivedi, Saad Khan, Neil B Desai, Aaron Laine, Kevin Albuquerque, Puneeth Iyengar, Yull Arriaga, Kevin Courtney, David E Gerber, Hans Hammers, Hak Choy, Robert Timmerman, James Brugarolas, Raquibul Hannan,

Integration of hypofractionated body radiotherapy (H-RT) into immune checkpoint inhibitor (ICI) therapy may be a promising strategy to improve the outcomes of ICIs, although sufficient data is lacking regarding the safety and efficacy of this regimen. We, hereby, reviewed the safety and efficacy of this combination in 59 patients treated ... Read more >>

Oncoimmunology (Oncoimmunology)
[2018, 7(7):e1440168]

Cited: 2 times

View full text PDF listing >>



TNF-driven adaptive response mediates resistance to EGFR inhibition in lung cancer.

Ke Gong, Gao Guo, David E Gerber, Boning Gao, Michael Peyton, Chun Huang, John D Minna, Kimmo J Hatanpaa, Kemp Kernstine, Ling Cai, Yang Xie, Hong Zhu, Farjana J Fattah, Shanrong Zhang, Masaya Takahashi, Bipasha Mukherjee, Sandeep Burma, Jonathan Dowell, Kathryn Dao, Vassiliki A Papadimitrakopoulou, Victor Olivas, Trever G Bivona, Dawen Zhao, Amyn A Habib,

Although aberrant EGFR signaling is widespread in cancer, EGFR inhibition is effective only in a subset of non-small cell lung cancer (NSCLC) with EGFR activating mutations. A majority of NSCLCs express EGFR wild type (EGFRwt) and do not respond to EGFR inhibition. TNF is a major mediator of inflammation-induced cancer. ... Read more >>

J. Clin. Invest. (The Journal of clinical investigation)
[2018, 128(6):2500-2518]

Cited: 4 times

View full text PDF listing >>



Advertisement

Disclaimer
1.4371 s